Mode
Text Size
Log in / Sign up

High-dose quadrivalent influenza vaccine shows non-inferior immunogenicity in Chinese children aged 6 to 35 monthsHigh-dose flu shots show greater protection for young children in China

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider the investigational high-dose quadrivalent influenza vaccine for children aged 6 to 35 months based on non-inferior immunogenicity and superior immune response in this Chinese study.

This was a randomized, double-blind clinical study conducted in China. The population consisted of 3,000 children aged 6 to 35 months. The study setting was China. The intervention was an investigational high-dose quadrivalent influenza vaccine (H-QIV). The comparators were an investigational low-dose quadrivalent influenza vaccine (LQIV-01) and a commercially available low-dose quadrivalent influenza vaccine (LQIV-02). The primary outcome was the non-inferiority of the investigational vaccines to the commercially available vaccine in immunogenicity. The follow-up period was 6 months.

The main results for immunogenicity showed that both investigational vaccines demonstrated non-inferiority to the commercially available vaccine. For hemagglutination inhibition (HI) antibody titers, H-QIV exhibited >11-fold increases compared to pre-vaccination levels against H1N1, H3N2, B/Yamagata, and B/Victoria strains. The seroprotection rates (SPRs) exceeded 95%. The seroconversion rates (SCRs) exceeded 89%. The immune response strength was superior for H-QIV compared to both L-QIVs.

Key secondary outcomes included the comparison of H-QIV to the low-dose investigational and commercial vaccines. The data showed H-QIV was superior in immune response strength. The study also reported hemagglutination inhibition (HI) antibody titers, with H-QIV showing >11-fold increases. Safety and tolerability were also key secondary outcomes.

Safety and tolerability findings indicated comparable safety profiles across all vaccine groups. The adverse event rates were comparable. Serious adverse events were not reported. Discontinuations due to adverse events were not reported. The tolerability was reported as comparable safety profiles.

These results can be compared to prior landmark studies in influenza vaccination. However, the specific prior studies are not reported in the input data. The current study provides evidence in a pediatric population in China, which may differ from previous studies conducted in other regions or age groups.

Key methodological limitations are not reported in the input data. Potential biases cannot be assessed from the provided information. The study was randomized and double-blind, which helps reduce bias, but the absence of reported limitations means the full context of potential biases is unknown.

For clinical practice, the results suggest that H-QIV can provide greater protection and benefits to this high-risk population of young children. However, the evidence is specific to the studied population and setting. Clinicians should interpret these findings within the context of the available data and consider them as part of the broader evidence base for influenza vaccination in children.

Unanswered questions remain regarding the long-term durability of the immune response beyond 6 months, the effectiveness in preventing clinical influenza disease, and the generalizability to other populations or regions. Further research is needed to address these gaps.

Flu season brings worry to many parents, especially those with young children. Kids aged six to thirty-five months are at high risk for severe illness from the flu virus. A new study offers hope for better protection in this vulnerable group. Researchers in China wanted to see if a high-dose flu vaccine could offer stronger defense than the standard low-dose shots currently available. This is important because young children often have weaker immune systems that struggle to fight off infections effectively.

The study involved three thousand children in China. They were randomly assigned to receive either the investigational high-dose quadrivalent influenza vaccine or a low-dose version. The low-dose group received either an investigational low-dose vaccine or a commercially available low-dose vaccine. The term quadrivalent means the shot protects against four different strains of the flu virus. The researchers followed the children for six months to see how well their bodies responded to the shots.

The results were clear and positive. Both the high-dose and low-dose vaccines proved to be non-inferior to each other in terms of basic immune response. However, the high-dose vaccine showed superior immune response strength compared to the low-dose options. The high-dose vaccine caused more than eleven-fold increases in antibody levels compared to pre-vaccination levels. This means the body built up a much stronger shield against the virus. More than ninety-five percent of children developed protective antibodies, and more than eighty-nine percent developed antibodies that could stop the virus from entering cells.

Safety was a major concern for the researchers and parents alike. The study found comparable safety profiles between the high-dose and low-dose vaccines. No serious adverse events were reported during the trial. No children had to stop taking part in the study due to side effects. The high-dose vaccine was well-tolerated by the young participants. This is a crucial finding because parents often worry that stronger shots might cause more pain or illness.

It is important to remember that this is a single study conducted in one specific setting in China. While the results are promising, people should not overreact or assume this applies everywhere immediately. The high-dose vaccine can provide greater protection and benefits to this high-risk population of young children. However, the standard low-dose vaccine remains a valid option for now. This research gives doctors and parents more options to choose the best protection for their little ones when flu season arrives.

What this means for you:
High-dose flu vaccine showed superior immune response and comparable safety in young children.

Study Details

Study typeRct
Sample sizen = 3,000
EvidenceLevel 2
PublishedDec 2026
View Original Abstract ↓
Influenza vaccines for children aged 6-35 months are typically low-dose (0.25 mL, 7.5 μg hemagglutinin per strain). However, studies have shown that high-dose influenza vaccines (0.5 mL, 15 μg hemagglutinin per strain) can enhance protective efficacy without increasing the risk of adverse reactions. We conducted a randomized, double-blind clinical study in children aged 6-35 months in China. A total of 3,000 participants were randomized (1:1:1) to receive two doses of either an investigational high-dose quadrivalent influenza vaccine (H-QIV), an investigational low-dose quadrivalent influenza vaccine (LQIV-01) or a commercially available low-dose quadrivalent influenza vaccine (LQIV-02). Hemagglutination inhibition (HI) antibody titers 30 d post-vaccination were measured and vaccine safety and tolerability within 6 months post-vaccination were evaluated in these participants. The primary objectives were to demonstrate the non-inferiority of investigational vaccines to the commercially available vaccine in immunogenicity and to compare the H-QIV to L-QIVs. Both investigational vaccines demonstrated non-inferiority, with their seroprotection rates (SPRs), seroconversion rates (SCRs) and geometric mean titers (GMTs) meeting immunogenicity criteria. The H-QIV exhibited >11-fold increases in GMTs against H1N1, H3N2, B/Yamagata and B/Victoria strains compared to pre-vaccination levels, with SPRs exceeding 95% and SCRs exceeding 89%. The H-QIV was superior to both L-QIVs as it induced a stronger immune response to influenza viruses. All vaccines showed comparable safety profiles. The H-QIV can provide greater protection and benefits to this high-risk population.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.